Vanguard Capital Management’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14M Buy
4,579,587
+56,947
+1% +$189K ﹤0.01% 2582
2026
Q2
$16.7M Buy
4,522,640
+48,478
+1% +$161K ﹤0.01% 2548
2026
Q1
$15.6M Buy
+4,474,162
New +$17M ﹤0.01% 2483

Other funds holding PRME

Vanguard Capital Management's PRME Position: Q3 2026 in Review

Vanguard Capital Management increased its Prime Medicine (PRME) stake by 1.3% in Q3 2026, buying an estimated $189K and bringing the position to 4,579,587 shares worth $14M. The position accounts for ﹤0.01% of the portfolio, ranked #2582.

Vanguard Capital Management first reported a position in PRME in Q1 2026 and has held it in 3 quarters since. The position peaked at $16.7M in Q2 2026. 185 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Vanguard Capital Management held 4,579,587 shares of Prime Medicine worth $14M as of Q3 2026.
  • Vanguard Capital Management bought 56,947 Prime Medicine shares in Q3 2026, an estimated $189K.
  • Prime Medicine made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2582 holding.
  • Vanguard Capital Management first reported a position in Prime Medicine in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Prime Medicine position peaked at $16.7M in Q2 2026.
  • 185 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.